WO1996028966A1 - Transformant de mammifere autre que primate et dont un serotype de primate superieur s'exprime par transduction d'un gene etranger, procede de fabrication de ce transformant - Google Patents
Transformant de mammifere autre que primate et dont un serotype de primate superieur s'exprime par transduction d'un gene etranger, procede de fabrication de ce transformant Download PDFInfo
- Publication number
- WO1996028966A1 WO1996028966A1 PCT/JP1995/000488 JP9500488W WO9628966A1 WO 1996028966 A1 WO1996028966 A1 WO 1996028966A1 JP 9500488 W JP9500488 W JP 9500488W WO 9628966 A1 WO9628966 A1 WO 9628966A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- primate
- gene
- animal
- mammal
- foreign gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 83
- 241000288906 Primates Species 0.000 title claims abstract description 78
- 241000124008 Mammalia Species 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title description 27
- 230000008569 process Effects 0.000 title description 4
- 230000026683 transduction Effects 0.000 title 1
- 238000010361 transduction Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 102000004357 Transferases Human genes 0.000 claims abstract description 8
- 108090000992 Transferases Proteins 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims description 51
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 28
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000002054 transplantation Methods 0.000 claims description 13
- 230000009261 transgenic effect Effects 0.000 claims description 12
- 101150054603 ft gene Proteins 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 150000008195 galaktosides Chemical class 0.000 claims description 3
- 230000006098 transglycosylation Effects 0.000 claims description 3
- 238000005918 transglycosylation reaction Methods 0.000 claims description 3
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 claims description 2
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 claims description 2
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 claims description 2
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010011469 Crying Diseases 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 abstract description 6
- 230000002463 transducing effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 50
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 241000282412 Homo Species 0.000 description 17
- 235000013601 eggs Nutrition 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 14
- 210000000601 blood cell Anatomy 0.000 description 13
- 210000004204 blood vessel Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 108020004491 Antisense DNA Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000003816 antisense DNA Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 101150099983 GT gene Proteins 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 4
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 4
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 4
- 239000002473 artificial blood Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000005167 vascular cell Anatomy 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- HEAUFJZALFKPBA-JPQUDPSNSA-N (3s)-3-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-JPQUDPSNSA-N 0.000 description 3
- 101150033839 4 gene Proteins 0.000 description 3
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101001027678 Mus musculus Gastrotropin Proteins 0.000 description 3
- 101800000399 Neurokinin A Proteins 0.000 description 3
- 102100024304 Protachykinin-1 Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101150034814 F gene Proteins 0.000 description 2
- 241001507252 Japanese monkeys Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000406668 Loxodonta cyclotis Species 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- 241000282405 Pongo abelii Species 0.000 description 2
- 101001027675 Sus scrofa Gastrotropin Proteins 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000774651 Naja atra Zinc metalloproteinase-disintegrin-like kaouthiagin-like Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- WASXNYRXXQONPG-UHFFFAOYSA-N Rubia akane RA-VI Natural products C1=CC(OC)=CC=C1CC(N(C)C(=O)C(CO)NC(=O)C(C)NC(=O)C(N(C1=O)C)C2)C(=O)NC(C)C(=O)N(C)C1CC(C=C1)=CC=C1OC1=CC2=CC=C1OC WASXNYRXXQONPG-UHFFFAOYSA-N 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000469 anti-sperm effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010071967 protein K Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
Definitions
- Rui a non-primate mammal expressing a higher primate antigen by the introduction of a foreign gene W transgenic animal and its production method
- the present invention relates to a method for producing a transgenic animal of non-primates with non-primates, including a cell transplanted into a higher primate, a transgenic non-primate beaked animal, and the like, and Converts sugar antigens of non-primate mammals into a form unique to higher primates,
- the higher 38 primates refers to the narrow forests a belonging to human primates, orangutans, baboons, Japanese monkeys, etc. among the true suborders of primates.
- the non-higher spirits refer to the broad-spectrum Ao and Omena among the genus Monkeys.
- Non-primate baby s or non-s longid W milk animal is a non-primate mammal
- a tissue includes ⁇ 3 ⁇ 4 such as »11 and liver n, as well as skin, blood vessels, and» vesicles.
- an artificial material represented by an artificial »# or an artificial blood vessel is used as a substitute for such a tissue. This includes self-tissues, and even the same or different animal tissues.
- braids extracted from such dairy animals are known to cause severe rejection in humans, and in particular, rejection that occurs within 24 hours of censorship. This is also called acute rejection.
- hyperacute rejection occurs in the blood vessels of the donor tissue during the blood flow by anastomosing the blood vessels of the replenished donor tissue with the blood vessels of the recipient.
- This hyperacute rejection in combination with humans or species with natural antibodies, is the classical pathway triggered by the anti-K antibody response of the two activated S pathways of the human complement system. Is thought to be the main chestnut reaction. This antigen-antibody reaction is thought to be due to the following causes.
- the antigenicity on the vascular ia vesicle and blood cell system (hereinafter also referred to as vascular and blood cell system iffl ⁇ ) containing the vascular endothelium of non-primate beaked mammals such as septum is considered to be low. This is because it is different from that of the higher primates such as G.
- non-spirit fi mammals such as stags
- GS anti-JF anti-K
- GS anti-JF anti-K
- the precursor of the GS antigen is added to the donor tissue, and before that, the B substance K is also a so-called Bombay 1 [because it is an antigen, it is still a natural antibody still present in humans. Acute rejection will result.
- the substance H according to the present invention acts on the substance K (N-acetyllactosamine) with GDP-fucose: galactoside 2- ⁇ -lefucosyltransferase (hereinafter simply referred to as FT).
- the produced GS substance is UDP-galactose for N-acetyllactosamine, which is the same precursor as the above-mentioned H-type substance: yS-D-galactosyl-1,4-N-acetyl-D-darcosamino2 It is produced by the action of ⁇ -1.3-galactosyltransferase (hereinafter referred to as GT on cars).
- the difference between the antigen S in the blood vessels and blood cells in humans and the like is due to the difference in the enzymes acting on the 18 substances, in other words, the enzyme GT in the blood and the like. It is based on the difference that the enzyme GT exists and the enzyme F does not exist in humans and the like.
- the presence or absence of ABHS substances and enzymes in such various tissues is considered to be based on evolution.
- the present invention provides a novel method for solving WS in conventional xenograft transplantation using non-conventional new methods in non-S long W mammals such as pusta which are widely grown and easily available as a family.
- An object of the present invention is to alleviate hyperacute rejection at the time of transplantation and apply a non-primate W milk animal to transplantation into higher primates.
- the present inventor has developed a high S-length S glycosyltransferase such as FT in non-JI long-range ft animals such as epta, in terms of gene engineering and developmental engineering.
- the present invention can be said to be a more K-like solution S than the conventional method in that the binding itself between the natural anti-G antibody and the GS antigen in higher primates such as humans is suppressed.
- Transgenic animals of the non-primate ⁇ such present invention is especially ft to have glycosyltransferase ⁇ foreign ⁇ Ko which Ru is expressed in higher primates ⁇
- exogenous “genes” may be held in the form of “Het ⁇ ” or in the form of “Homo”, but are preferably held in the form of “Homo”.
- the animal may in particular also have a foreign gene that expresses FT as a glycosyltransferase of higher primate S.
- the animal of the present invention comprises a first exogenous tract gene that expresses a glycosyltransferase of a higher primate, and a second exogenous gene that suppresses the expression of «transferase in a non-primate primate.
- a glycosyltransferase of the higher length such as FT
- a glycosyltransferase of the non S length mammals can be GT beta
- exogenous a genes may be stored in a heterogeneous form 1 or in a homozygous state us, but are preferably maintained in a homozygous form].
- the non-primate beaked mammal of the present invention can be a primate.
- the tissue obtained from the animal of the present invention can be widely used as a transplant material for the second and higher stages of ⁇ .
- the method of the present invention expresses a higher S-long glycosyltransferase.
- the first outpatient ⁇ A second exogenous gene that suppresses the expression of glycosyltransferase in a gene and / or non-S long babies Higher S-long antigen S that specially introduces genes into non-two-long babies This is a method for producing a transformed animal of a non-S long mammal that expresses S.
- the present invention will be described in detail.
- non-primate W dairy animals such as Puyu
- G T instead of F T
- K G-type substance
- an exogenous gene fragment containing the FT Liao gene encoding the transferase FT which produces an HS substance from the substance E before it, is introduced into a recipient egg such as a pig, and this gene fragment is transferred to the chromosome.
- a recipient egg such as a pig
- this gene fragment is transferred to the chromosome.
- the enzyme removes the pre- ⁇ 3 ⁇ 4, it can be expected that the ring between the endogenous enzyme GT and pre-eei will be inhibited and the production of GSttiK will be suppressed.
- the FT gene can be stably transmitted to progeny after it has been incorporated into the chromosome.
- the expression of the gene for glycosyltransferase GT which produces glycosyltransferase II present in non-S-long S ⁇ ⁇ animals such as Pusan, for example, GS «) substance from substance B before In order to inactivate E.
- a foreign gene fragment containing the antisense DNA of the GT gene is equally introduced into the ovum. If this gene fragment is integrated on the chromosome of the body, If this antisense DNA is transcribed in ⁇ ⁇ , it is expected that the transcript I will be paired with the endogenous GT transcript and that the R of the GT gene will be suppressed.
- the foreign gene Once the foreign gene has been integrated into the chromosome, it can be transformed into a foreign * gene to form a homozygous JB by crossing, and it expresses higher glycosyltransferases.
- humans can be particularly targeted as the higher S longs.
- non-lingual long babies an animal which is a target of xenotransplantation with respect to the 32 higher S long chains can be targeted. Furthermore, bush, sea lions, sheep, goats, etc., raised as domestic animals, are preferred. Since these livestock are easy to raise and can be supplied in a stable manner, they are suitable for replenishing tissue for transplantation. In addition, stags are fast because of the size of IR8, physiological and biochemical points of view, and their rapid development and high production. Higher S long-chain glycosyltransferases are glycosyltransferases that are found in higher S longs and that contribute to the generation of anti-surfaces that are not found in non-3 long mammalian vasculature and blood cells. Say.
- ⁇ capable of increasing FT is specified by [EC 2.4.1. ⁇ ].
- An exogenous gene that expresses a glycosyltransferase cord of a higher primate may have a promoter, a terminator, etc., in addition to the glucosyltransferase gene.
- SV40 early inheritance Yuichi Minei Yuichi is one of the E rows suitable for addition. The level of gene expression greatly depends on the poly-A signal from which one of the transgenes is taken, but the early stage of SV40 ⁇ Boli A addition from the gene I have. This signal is placed before the evening minator.
- foreign genes can be constructed for homologous recombination as well as non-reciprocal recombination in chromosomes.
- the pig GT gene is targeted and the human FT gene is recombined, it is possible to suppress the expression of GT and to express FT at the same time.
- a means in which the transferase is expressed at a high rate can be used for the gene fragment or chromosome that has been recombined.
- high expression can be induced by steroid administration.
- Glycosyltransferase with non-s-length m milk is found in vascular and blood cells of non-S-length W mammals and is a glycosyltransferase that contributes to the production of antigens that are not found in primates such as 5555. .
- the mouse GT is specified in [EC 2.4.1.15 1].
- Non-S long lactating exogenous genes that suppress the expression of glycosyltransferase in lactate S include: antisense DNA against the translocated transgenic hatchling gene and homologous genes in the glycosyltransferase. Introduced to replace the * «gene by replacing the ⁇ gene with another Liao gene, conducting another gene in the K * gene, or introducing a mutation. * Can use a gene.
- the mouse GT3 ⁇ 4 gene has already been reported (Proc, atl. Acad. Sci. USA. 86 (1989). Pp. 8227-8231). The pig GT gene has also been reported (Xeno tr ansp lant atti on 1994; 1: PP.81-88).
- the antisense DNA of GT when used as an exogenous gene, a fragment in which Ichiro or all of the cDNA of GT gene is incorporated in the antisense direction is formed as an exogenous gene.
- non-S length In order to suppress the expression of glycosyltransferases, a conventionally known method can be used in addition to the introduction of a foreign gene. There are many methods for introducing an exogenous gene into a non-primate mammal, such as a method using a retrovirus or a method using a microinjector, and any method can be adopted. In order to obtain offspring, it is desirable to transform the cells. In this case, it is desirable that the transformation be performed on embryo blasts and ES vesicles of non-primate PH animals, or on the recipient ft.
- non-primate mammals into which the foreign gene has been introduced can be expressed by the expression of glycosyltransferase of higher primates in various cells or simultaneously with the expression of glycosyltransferase of non-mammal mammals.
- the suppression results in an animal whose ⁇ BSi of the braid and blood is approximated to a higher octagon. Therefore, it becomes possible to ⁇ -reduce hyperacute rejection when the tissues 9 of these animals are transplanted into higher primates, and the tissues of these animals can be transferred to primates such as S. It will be faster.
- ⁇ -acute rejection is greatly reduced, especially when expressed in vascular endothelium.
- one or more GT gene loci on the chromosome do not exist, and Since at least one FT will be present at the time of cultivation, it is possible to obtain an individual that has neither GT nor one on the chromosome by crossing, and instead has two FTs.
- These valences provide the transplanted material for transplantation in humans and the like as a donor, regardless of the recipient's ABO blood type.
- a transformed non-S long mammal W has a tissue and blood which can be transplanted into a higher primate such as a human, it is possible to provide a substitute for a tissue such as a human. It becomes.
- a method for providing an animal or material that can mitigate super elephant rejection in the case of xenogeneic M transplantation by expressing the FT gene specific to higher S-mammals in non-S-mammal lambs is a novel novel method. As well as providing a more essential solution for the mitigation of neutrophil rejection in xenografts.
- non-primate transgenic animal of the present invention a higher primate sugar tt anti-stable is produced in the tissue and blood, or a non-primate ⁇ milk sugar ⁇ antigen Since the production of non-primate Tate mammals is suppressed, hyperacute rejection ffi can be mitigated when the tissue of a non-primate Tateyama mammal is transplanted to a higher primate, which is a xenograft transplant. It is possible to provide a material which can be replaced by the same kind or the like.
- transforming non-primate primates according to the present invention does not cause any damage or refuge to these animals, and the present invention provides a method for transforming non-primate primates. It has no effect on survival, life, etc. Further, the present invention does not affect humans or any other animals, including humans.
- FIG. 1 is a diagram showing the synthesis of the ABHStt substance and the GS substance from the precursor (N-acetyl lactosamine).
- 02 is an as plane for constructing and operating the plasmid pMAM / FT having the FT gene of Example 1.
- H3 is a model B of the fragment for introducing an FT gene in Example 1.
- H4 shows a process diagram for “building” pREP 885/0 in Example 2.
- FIG. 6 is a process diagram for constructing the tank of PREP 9 / GT3-4 of the third embodiment.
- E7 is pREP 9 / GT3-4ZFT / m S s p l / ⁇ r a I of Example 3.
- FIG. 8 shows a process 0 for constructing and operating p GTZFT of the third embodiment.
- B9 is a graph 0 showing the result of “Cr release attestation.
- RNA was extracted, and CDNA corresponding to total RNA was synthesized using reverse transcriptase. Using this cDNA as a primer, PCR was performed using the previous primer.
- MCS multiple cloning site
- the LB medium Composition: Bacto-tryprone 10g (manufactured by DIFC0), Bacto-yeast extract 5g (manufactured by DIPC0), and aCl 10g made up to 1L with water, the same shall apply hereinafter).
- Mini Brasmid W made.
- the extracted brassmid DNA was digested with various restriction enzymes and then electrophoresed to determine the size and position of the inserted fragment.
- the brassine that was assembled in the right direction was called pMAM / FT (see 02).
- Escherichia coli JM109 / p MAM / FT strain was mass-cultured in LB, and then subjected to plasmid 39 in order to obtain a straight ft-shaped fragment for gene transfer. Further, the obtained plasmid was purified by CsC1 density gradient E centrifugation. The purified plasmid 1 Otfg is digested with Pvu I and BamHI, and this fragment is purified.
- RNA was extracted, and cDNA corresponding to the total RNA was synthesized using reverse transcriptase. This cDNA was transformed into a »form, and PCR was performed using the above primers.
- the cDNA fragment obtained by this PCR was subjected to electrophoresis on 1 ⁇ GALOS gel. As a result, a band having a length of about llOObp was obtained.
- the base sequence was determined using an automatic S-sequence reader. I was Therefore, this cDNA was electrophoresed on an LMP gel, purified, treated with the R enzymes Nhel and Xhol, and separated by ft using the Wizard system.
- the extracted brassmid DNA was digested with various restriction enzymes and electrophoresed to determine the size and orientation of the input fragments.
- the plasmid correctly incorporated in the antisense direction was called PREP 8ZASZGT (see Fig. 4).
- plasmids were produced after large-scale fertilization of the O. seedling JM109 / ⁇ REP8 / ASZGT strain in LB * ground. . Furthermore, the obtained plasmid was refined by Cs C l * gradient « « heart method Colour 1 After digestion of 10 g of the prepared plasmid with the control element Xba I and Pst I, this fragment was purified and separated by LMP gel «Swimming and Wizard system, and the fragment for ASZGT * gene transfer was obtained. And A schematic diagram of the construction of this fragment is shown in FIG.
- a primer with a cleavage site of the ⁇ -strand Kpn I as the sense primer of exon 3 (pZA) and an antisense primer A primer (p / B) containing a restriction enzyme S8pI cleavage site at the start codon site of exon 4 ⁇ and a downstream cleavage site of the restriction enzyme HindII1 was synthesized.
- pREP9 an expression vector, was digested with BamHI, a ⁇ -enzyme cable, and its cleavage was smoothed with T4 DNA polymerase, followed by ligation with T4 DNA ligase.
- the expression vector in which the cleavage site of I was deleted was designated as pREP9 / mBamHI.
- both ends were controlled by elimination, and the FT cDNA expression initiation site was located at the beginning of the GT.
- This plasmid was designated as pREP 9ZGT 3-4 / FT / ASspI / ADraIlI.
- all of these 15 elements, Kpn Hl nd ll Ss p I, Nhe I, Dra III, and Xho 1 were able to convert the fragments from exon 3 to exon 4 and the fragment at the top of the expression of FT cDNA. Do not cut or H is bitten.
- An antisense primer (p / E) was synthesized in a form that contained the 3 ′ primate of p01 yA of pREP 9 and also contained a restriction site BamHI cleavage site. This was combined with the sense primer (p / A).
- pREP 9 / GT 3-4 / FT / m S sp I / AD ra III use? The 13 ⁇ 4 method was carried out, and the obtained fragment was cut with control elements Kpn I and BamHI, divided by ⁇ 3 ⁇ 4 ⁇ , and the obtained fragment was called GT 3-4 / FT / p 01 yA.
- the expression vector pREP9 was digested with the IRB elements KpnI and BamHI, and the above fragment GT3-4 / FT / p01yA was entered. This is pREP9 / GT3 1 4 / FT / po] y It was called A.
- a portion from GT exon 4 to exon 6 or exon 7 is cut by restriction enzyme BamHI for both sense primer (p / F) and antisense primer (PZG), and extracted by PC method.
- This fragment was cleaved with K ⁇ * BamH I, and the obtained fragment was subjected to plasmin FpREPSZGT 3—4 / FT / p01yA opened with the R enzyme BamH I (BamH I, GT 3-4, FT, po1yA and T4-17 have not been cut previously).
- the resulting plasmid was called pREP 9 / GTZFT on 13 ⁇ 4 £ 9 (? C3-4 / C / 01 yA / GT4-7, or «! Car.
- the Primer p / A and PCR was performed using pZG
- the fragment obtained after ft production was used as a fragment for introduction into fertilized eggs, and was referred to as GT3-4ZFTZP01A / GT4-7, or simply pGTZFT.
- the 3 ⁇ 4 gene fragment for introduction which was created as described above, has high homology to the * gene on the chromosome of GT and is expected to cause homologous recombination.
- FT is used instead of GT
- the expression (Fo) results in the expression of both GT and FT, but after one or two generations of crossing, it is possible to obtain a valence having only FT according to Mendel's law.
- non-primate ⁇ is a transgenic animal that has no antigen specific to mammals but has an antigen specific to higher primates. Since the homology between T and Busu GT is high, homologous recombination based on mouse GT can be used quickly.
- fragments for introduction should be IB-rinsed with TE «3 ⁇ 43 ⁇ 4 (0.25mM EDTA, 5mM Tris (pH7.4)), and IB rinsed to 1.0 each. ⁇ The product made from I was used.
- the cells were cultured in an M2 medium for 2 to 3 hours in a CO. Incubator, and then the fertilized eggs were transplanted into oviducts of ⁇ -mature pigs in estrus. Transplantation was performed by Mffift under intrasystemic hepatitis »tubal transfer tt. Fallopian tube transfer. The animals were bred up until the postpartum period to give birth.
- the fertilized eggs into which the gene has been injected are immediately transplanted.
- cDNA was synthesized from total RNA using reverse transcriptase, and PCR was performed using the primers used for FT gene extraction described above.
- One in 27 of the sugar fruits was determined to be »sex.
- the introduced FT * gene was converted into mRNA and produced the FT enzyme protein K.
- a similar search was performed for the control puta 15K into which no transgene was introduced, but all of them were found to be dangerous.
- Blood was collected from the pups that were determined to be BB in Example 6; that is, it is considered to be producing S white matter of FT. After centrifugation, blood cells were separated »FI using S photoantibodies. Putta blood cells were stained by the TC method. On the other hand, blood was also collected from the control puta (Buyu, who did not use the gene guide) and stained similarly.
- an anti-antibody was used as a primary antibody, and mouse 7 globulin (P (ab),) labeled with a fluorescent dye was used as a secondary antibody.
- P (ab) mouse 7 globulin
- the offspring of »sex in Example 6 were determined to be K sex.
- the blanking evening IF derived colonies sleeves vesicular systems PK 15 were infected with pMAM FT of and S-option, C. in culture plus ll C r, constant during 18 culture, then healthy adult human blood (A. (Including four blood types B, 0, and AB). "
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU19604/95A AU1960495A (en) | 1995-03-17 | 1995-03-17 | Transformant of nonprimatial mammal having serotype of advanced primate expressed by foreign gene transduction and process for producing the same |
PCT/JP1995/000488 WO1996028966A1 (fr) | 1995-03-17 | 1995-03-17 | Transformant de mammifere autre que primate et dont un serotype de primate superieur s'exprime par transduction d'un gene etranger, procede de fabrication de ce transformant |
PCT/JP1996/000703 WO1996028967A1 (fr) | 1995-03-17 | 1996-03-18 | Mammiferes transgeniques autres que des primates, ou des serotypes de primates superieurs ont ete exprimes par un transfert de genes etrangers et procede pour creer ceux-ci |
JP52828796A JP3809189B2 (ja) | 1995-03-17 | 1996-03-18 | 外来遺伝子の導入により高等霊長類の抗原型を発現した非霊長哺乳類の形質転換動物及びその作出方法 |
AU49562/96A AU4956296A (en) | 1995-03-17 | 1996-03-18 | Transgenic non-primatal mammals wherein serotypes of higher primates have been expressed by foreign gene transfer and method of creating the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1995/000488 WO1996028966A1 (fr) | 1995-03-17 | 1995-03-17 | Transformant de mammifere autre que primate et dont un serotype de primate superieur s'exprime par transduction d'un gene etranger, procede de fabrication de ce transformant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996028966A1 true WO1996028966A1 (fr) | 1996-09-26 |
Family
ID=14125774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000488 WO1996028966A1 (fr) | 1995-03-17 | 1995-03-17 | Transformant de mammifere autre que primate et dont un serotype de primate superieur s'exprime par transduction d'un gene etranger, procede de fabrication de ce transformant |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP3809189B2 (ja) |
AU (2) | AU1960495A (ja) |
WO (1) | WO1996028966A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01501363A (ja) * | 1986-11-14 | 1989-05-18 | ジェネティックス・インスチチュート・インコーポレーテッド | 真核細胞発現系 |
-
1995
- 1995-03-17 WO PCT/JP1995/000488 patent/WO1996028966A1/ja active Application Filing
- 1995-03-17 AU AU19604/95A patent/AU1960495A/en not_active Abandoned
-
1996
- 1996-03-18 JP JP52828796A patent/JP3809189B2/ja not_active Expired - Fee Related
- 1996-03-18 AU AU49562/96A patent/AU4956296A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01501363A (ja) * | 1986-11-14 | 1989-05-18 | ジェネティックス・インスチチュート・インコーポレーテッド | 真核細胞発現系 |
Non-Patent Citations (3)
Title |
---|
PROC. NATL. ACAD. SCI. U.S.A., Vol. 86, No. 21, (1989), ROBERT D. LARSEN et al., "Isolation of a cDNA Encoding a Murine UDP Galactose: Beta-D-galactosyl-1,4-N-acetyl-D-glucosaminide Alpha-1,3-galactosyltransferase: Expression Cloning by Gene Transfer", pages 8227-8231. * |
PROC. NATL. ACAD. SCI. U.S.A., Vol. 87, No. 17, (1990), ROBERT D. LARSEN et al., "Molecular Cloning, Sequence and Expression of a Human GDP-L-fucose: Beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA that can Form the H Blood Group Antigen", pages 6674-6678. * |
PROC. NATL. ACAD. SCI. U.S.A., Vol. 92, No. 5, (1995), PER G. FALK et al., "Expression of a Human Alpha-1,3/4-fucosyltransferase in the Pit Cell Lineage of FVB/N Mouse Stomach Results in Production of Leb-containing Glycoconjugates: a Potential Transgenic Mouse Model for Studying Helicobacter Pylori Infection", pages 1515-1519. * |
Also Published As
Publication number | Publication date |
---|---|
JP3809189B2 (ja) | 2006-08-16 |
AU4956296A (en) | 1996-10-08 |
AU1960495A (en) | 1996-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prather et al. | Genetically modified pigs for medicine and agriculture | |
US6166288A (en) | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor | |
DE69534227T2 (de) | Stoffe und verfahren zur beherrschung der hyperakuten abstossung von menschlichen transplantaten | |
US11160260B2 (en) | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) | |
EP3331355A1 (en) | Pathogen-resistant animals having modified cd163 genes | |
US20020152488A1 (en) | Genetically engineered animals for use as organ donors | |
AU2002308533B2 (en) | Modified organs and cells for xenotransplantation | |
KR20180100303A (ko) | 키메라 배아-보조 기관 생성을 위한 조성물 및 방법 | |
JPH09508277A (ja) | ヒト異種移植における超急性拒絶の管理のための物質及び方法 | |
US20060015955A1 (en) | Alpha(1,3)Galactosyltransferase enzyme that assembles the Galalpha(1,3)Gal xenoantigen | |
WO1996028967A1 (fr) | Mammiferes transgeniques autres que des primates, ou des serotypes de primates superieurs ont ete exprimes par un transfert de genes etrangers et procede pour creer ceux-ci | |
KR20180128386A (ko) | 유전적 상보성에 의한 인간화 신장의 조작 | |
WO2002015681A1 (fr) | Mammiferes transgeniques | |
Yazaki et al. | Successful cross‐breeding of cloned pigs expressing endo‐β‐galactosidase C and human decay accelerating factor | |
WO1996028966A1 (fr) | Transformant de mammifere autre que primate et dont un serotype de primate superieur s'exprime par transduction d'un gene etranger, procede de fabrication de ce transformant | |
Thall | Generation of α1, 3galactosyltransferase deficient mice | |
Sandrin et al. | Overcoming the anti-galα (1–3) gal reaction to avoid hyperacute rejection: Molecular genetic approaches | |
JPWO2005021769A1 (ja) | レンチウイルスベクターによる遺伝子導入鳥類作製法及びそれによって得られる遺伝子導入鳥類 | |
KR20210005074A (ko) | 바이러스에 의한 감염으로부터 돼지 태아를 보호하는 방법 | |
KR102594009B1 (ko) | 형질전환 생식세포의 제조 방법 및 이를 이용한 형질전환 동물의 제조 방법 | |
JP4995574B2 (ja) | 遺伝子導入鳥類作製法 | |
Nottle et al. | Transgenic perspectives in xenotransplantation, 2001. | |
Petitte | The avian germline and strategies for the production of transgenic chickens | |
AU711144B2 (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation | |
Wells | Conference XI |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 913689 Date of ref document: 19971110 Kind code of ref document: A Format of ref document f/p: F |